Insulet/$PODD
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Insulet
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Ticker
$PODD
Sector
Primary listing
Employees
3,900
Headquarters
Website
Insulet Metrics
BasicAdvanced
$21B
85.83
$3.45
1.38
-
Price and volume
Market cap
$21B
Beta
1.38
52-week high
$354.88
52-week low
$230.05
Average daily volume
723K
Financial strength
Current ratio
2.871
Quick ratio
1.883
Long term debt to equity
72.068
Total debt to equity
77.841
Interest coverage (TTM)
7.97%
Profitability
EBITDA (TTM)
524.4
Gross margin (TTM)
71.46%
Net profit margin (TTM)
9.76%
Operating margin (TTM)
16.79%
Effective tax rate (TTM)
20.79%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
8.74%
Return on equity (TTM)
19.68%
Valuation
Price to earnings (TTM)
85.832
Price to revenue (TTM)
8.257
Price to book
15.05
Price to tangible book (TTM)
16.97
Price to free cash flow (TTM)
51.083
Free cash flow yield (TTM)
1.96%
Free cash flow per share (TTM)
5.798
Growth
Revenue change (TTM)
27.11%
Earnings per share change (TTM)
-39.84%
3-year revenue growth (CAGR)
26.58%
10-year revenue growth (CAGR)
25.87%
3-year earnings per share growth (CAGR)
146.93%
10-year earnings per share growth (CAGR)
14.24%
What the Analysts think about Insulet
Analyst ratings (Buy, Hold, Sell) for Insulet stock.
Insulet Financial Performance
Revenues and expenses
Insulet Earnings Performance
Company profitability
Insulet News
AllArticlesVideos
Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience
Business Wire·6 days ago
Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
Business Wire·3 weeks ago
PODD Vs. Intuitive Surgical: This Underdog Might Just Win
Forbes·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Insulet stock?
Insulet (PODD) has a market cap of $21B as of December 10, 2025.
What is the P/E ratio for Insulet stock?
The price to earnings (P/E) ratio for Insulet (PODD) stock is 85.83 as of December 10, 2025.
Does Insulet stock pay dividends?
No, Insulet (PODD) stock does not pay dividends to its shareholders as of December 10, 2025.
When is the next Insulet dividend payment date?
Insulet (PODD) stock does not pay dividends to its shareholders.
What is the beta indicator for Insulet?
Insulet (PODD) has a beta rating of 1.38. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.